Article
14 Dec 2023
Biden Administration Releases Draft Framework For Exercising Bayh-Dole March-in Rights Taking Into Account Drug Prices
AUTHORS CONTENT
Article
17 Mar 2017
Janssen V. Celltrion: A Misstep In The BPCIA Patent Dance
Article
18 Jul 2016
En Banc Federal Circuit Clarifies Application Of On-Sale Bar To Contract Manufacturing
Article
12 Jul 2016
Federal Circuit Invites FDA's Early Licensure Of Biosimilars To Encourage Pre-Launch Resolution Of Patent Disputes
Article
29 Jun 2016
Supreme Court Defers To The Patent Office On Institution And Management Of Post-Grant Proceedings
Article
19 Aug 2015
Federal Circuit Expands Scope Of Liability For Divided Infringement
Article
27 Jul 2015
A Fractured Federal Circuit Panel Interprets The Biosimilars Patent Resolution Procedures
Article
03 Jul 2015
How Not To Get Snared In Brulotte's Web
Article
26 Feb 2015
Divided Federal Circuit Panel Upholds Patent Office’s "Broadest Reasonable Interpretation" Standard For Construing Claims In Post-Grant Review
Article
02 Feb 2015
Supreme Court Calls For Greater Deference To District Court Claim Construction
Article
30 Dec 2014
Federal Circuit’s Sandoz v. Amgen Decision Forecloses Early Declaratory
Article
30 Dec 2014
Federal Circuit’s Sandoz v. Amgen Decision Forecloses Early Declaratory Judgment Suits By Biosimilars Applicants
Article
10 Jun 2014
Supreme Court Decision Invites More Challenges To Patent Claims As Indefinite
Article
20 Feb 2012
FDA’s Draft Guidance On Scientific Considerations In Demonstrating Biosimilarity
Article
16 Feb 2012
FDA Releases Long-Awaited Draft Guidances On Biosimilar Product Development
Article
16 Jun 2011
Supreme Court Holds That Facts Underlying Patent Challenge Must Be Proved by Clear And Convincing Evidence
Article
07 Jan 2011
Federal Circuit Finds Method of Treatment Claims Patentable
Article
20 Aug 2010
Follow-on Biologics and Patent Reform: Will They Discourage Venture Capital Investment in the Biotechnology Industry?
Article
20 Apr 2010
Are Genes No Longer Patentable?
Article
25 Mar 2010
Biosimilars Pathway Enacted